

# Dissolution of Orally Inhaled Drugs using DissolvIt®: Influence of a Newly Designed Pre-Separator for Particle Collection

Beatriz Noriega<sup>1,2</sup>, Maria Malmlöf<sup>3,4</sup>, Eunice Costa<sup>1</sup>, M. Luisa Corvo<sup>2</sup>, Per Gerde<sup>3,4</sup>, Filipa M. Maia<sup>1</sup>

<sup>1</sup>Hovione FarmaCiencia SA, Sete Casas, Loures, 2674-506, Portugal <sup>2</sup>iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Avenida Prof. Gama Pinto, Lisboa, 1649-003, Portuga<sup>1</sup> <sup>3</sup>Inhalation Sciences, Hälsovägen 7-9, 141 57, Huddinge, Sweden

<sup>4</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

# Introduction

• Inhalation dosage forms present unique problems when developing a dissolution test due to their physicochemical properties and the physiological environment in which they should release their content.

**Dissolv***It*<sup>®</sup> was developed as a dissolution model which simulates the physiological conditions in the lung and mimics the pharmacokinetic data of inhaled particles<sup>[1]</sup>. It is used in combination with the PreciseInhale<sup>®</sup> exposure platform<sup>[2]</sup> to collect the aerosolized powder on glass coverslips by simulating human breath with an automated system.

• Moreover, only the **respirable fraction** of the dry powder (1-5 µm) should be considered in a dissolution test.

PreciseInhale® is equipped with an induction port (IP) simulating the patient's throat, however it does not completely separates the non-respirable fraction, leading to coarse

particle collection, and thus presence in the dissolution experiment.

In this work a newly designed pre-separator (PS) was employed during particle collection as an extra impaction stage for coarse particles, aiming to investigate the influence of the collected powder on the Dissolvlt<sup>®</sup> dissolution/absorption profiles.

# **Materials and Methods**

## **Powder characterization and collection on coverslips**

**1.** PreciseInhale<sup>®</sup> (Figure 1) was employed to aerosolize and collect the commercial powders on coverslips, to be tested in the Dissolv*It*<sup>®</sup> apparatus (Figure 2).




Figure 1 – Experimental set-up.

2. The number of actuations per API and set-up was selected to achieve similar deposited

# **Aerosol characterization**


The aerodynamic particle size of the powder was determined by Marple cascade impactor, coupled to the coating chamber during exposure at an airflow of 2 L/min.

The powder deposited in the coverslips was also analysed by SEM.

# **Dissolution profile determination with DissolvIt**®



Dissolution takes place in the **dissolution chamber**, from the coverslip glass to the pumped perfusate through a 50 µm-thick layer of mucus simulant and a polycarbonate membrane (0.03 µm pores).




#### doses.

**Table 1** – Amount of API deposited on the collecting glasses with the PreciseInhale<sup>®</sup>.

Set up	Inhaler	API	Deposited dose (ng/glass)	Number of actuations
Without PS	Flixotide Diskus	Fluticasone	651±293	1
With PS		Propionate (FP)	618±144	5
Without PS	Pulmicort	Budesonide (BD)	587±51	7
With PS	Flexhaler		739±62	3

### Eq.1: similarity factor






Figure 2 – DissolvIt® schematized, reprinted from [1];

# **Results and Discussion**

# Powder characterization and collection on coverslips

There is a significant decrease (p<0.05) in MMAD of the poder collected with using the PS for the FP powder (Figure 3, top).

BD powder collected with PS has a similar particle size **however** SEM results show less powder agglomerates.


# **Dissolution profile determination**

There is a **difference in the extent of dissolution between the APIs:** BD release increases to 85% in 2 hours, while FP does not reach 20% in 4 hours.

A **similar behaviour can be observed in clinical trials** of the studied drugs<sup>[1]</sup>.

# **PS** effect

FP collected with and without PS shows a **similar profile**, BD profiles show



#### a difference ( $f_2$ =0.38<0.50). Without PS:

 $\rightarrow$  **Slower dissolution**, which may be explained by the presence of larger agglomerates of particles on the glass coverslips visible to the naked eye, and therefore a reduced dissolution area (according to Fick's law)

 $\rightarrow$  Half maximum concentration of the dissolution profile

 $\rightarrow$  Longer half-life time, however, the time of maximum concentration was not influenced.

**Figure 3** – Left: SEM images from collected particles according to Table 1; Right: dissolution profile in the DissolvIt® apparatus, powder collection with (red) and without (black) the PS. n=3

# Conclusion

- The PS proved to have an influence on the powder aerodynamic profile and the API load collected on the coverslips.
- The dissolution results were not significantly different for Flixotide (FP), but for Pulmicort (BD) the **powder collected using the PS showed a higher dissolution rate**, possibly due to the deposition of smaller agglomerates, pointing to the importance of particle deagglomeration on API dissolution behaviour.
- Future work includes testing the inhalers with higher flow-rates and a new pre-separator appropriately designed for said flow-rates, to increase powder de-agglomeration and to better mimic the deposition of a fine particle fraction of an API in the real lung.

REFERENCES: [1] Gerde P, Malmlöf M, Havsborn L, Sjöberg CO, Ewing P, Eirefelt S, Ekelund K. Dissolv It: An In Vitro Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs. ASSAY and Drug Development Technologies. 2017 Mar 1;15(2):77-88. [2] Gerde P, Ewing P, Låstborn L, Ryrfeldt Å, Waher J, Lidén G. A novel method to aerosolize powder for short inhalation exposures at high concentrations: isolated rat lungs exposed to respirable diesel soot. Inhalation toxicology. 2004 Jan 1;16(1):45-52.